Researchers from The University of Texas MD Anderson Cancer Center showed that inhibiting menin with revumenib, previously known as SNDX-5613, yielded encouraging responses for advanced acute leukemias with KMT2A rearrangements ...
Mar 15, 2023
0
27
Unlike other forms of blood cancer, acute myeloid leukemia (AML) cannot currently be treated with CAR-T cell immunotherapy. The reason is that specific molecular targets with which certain immune cells could specifically ...
Mar 13, 2023
0
51
Myelodysplastic syndromes (MDS) are a diverse group of bone marrow disorders in which immature stem cells do not mature to become red blood cells, white blood cells or platelets. Patients with higher-risk MDS tend to have ...
Mar 9, 2023
0
19
A team of researchers has discovered a potential therapeutic that can synergize with existing drugs to more effectively kill certain leukemia cells. The authors published their results in Molecular & Cellular Proteomics.
Mar 8, 2023
0
9
Researchers at the National Institutes of Health show the benefits of screening adult patients in remission from acute myeloid leukemia (AML) for residual disease before receiving a bone marrow transplant. The findings, published ...
Mar 7, 2023
0
43
A new role for cohesin in regulating alternative splicing has been identified, providing insights into splicing mutations in human disease.
The latest research from SAHMRI and the University of Adelaide has discovered a potential new therapy for chronic myeloid leukemia (CML) patients who've achieved excellent results from current treatment and are hoping to ...
Mar 1, 2023
0
2
In elderly adults aged 60 years and older with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), allogeneic hematopoietic stem cell transplant (HSCT) can be performed with acceptable overall survival and nonrelapse ...
Feb 21, 2023
0
3
Residing in border regions was linked with a higher risk of dying within five years among children with acute lymphoblastic leukemia, the most common type of pediatric cancer.
Feb 21, 2023
0
40
Researchers at University of California San Diego School of Medicine, Sanford Stem Cell Institute and Moores Cancer Center report that a late-stage, pre-clinical small molecule inhibitor, called rebecsinib, reverses malignant ...
Feb 16, 2023
0
37
